STAT3 and neoplasm: Similarly, a recent study has demonstrated that the combination of osimertinib with repotrectinib (a multikinase inhibitor abrogating signaling by SFK members and JAK upstream of STAT3) causes tumor growth inhibition in EGFR-mutant cells, both in vitro and in vivo70.